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Mouse modelAlthough major progress has been achieved in treating breast cancer patients, metastatic breast
cancer still remains a deadly disease. A full understanding of the process of systemic cancer cell dis-
semination is therefore critical to develop next generation therapies. A plethora of experimental
data points toward a central role of an epithelial to mesenchymal transition (EMT) in the multistep
cascade of metastasis formation. However, in patients the data are based on correlative studies
which often, but not always, tie the expression of EMT markers to cancer invasion, metastasis
and poor clinical outcome. Moreover, the notion that cancer cells are able to switch between differ-
ent modes of migration asks for a thorough review of the actual relevance of EMT in cancer
metastasis.
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The role of an epithelial to mesenchymal transition (EMT) as a
fundamental biological mechanism is well established in mor-
phogenic processes of the developing embryo, in wound healing
and in organ ﬁbrosis [1–3]. In addition, an EMT is frequently called
upon – including by us – as a favored explanation how tumor cells
gain migratory and invasive properties in order to leave the pri-
mary tumor site, to disseminate throughout the body, and eventu-
ally form distant metastases [4–6]. In the prototypical multistep
model of metastasis, the function of EMT is attributed to the initial
events, when tumor cells lose their epithelial characteristics to
leave the primary tumor, invade into neighboring tissue and enter
the blood circulation (Fig. 1). An EMT is also thought to support the
survival of tumor cells in the blood stream and to promote extrava-
sation at the distant metastatic site [7,8]. Finally, mesenchymal
tumor cells that have undergone an EMT appear to share a variety
of hallmarks capabilities with experimentally deﬁned cancer stem
cells (CSC; for an in depth review of the link between EMT and CSC
see references [1,9]. Since mesenchymal carcinoma cells arethought to proliferate at reduced rates and since many carcinoma
metastases display the same degree of differentiation as their pri-
mary tumors, it is thought that mesenchymal, invasive cancer cells
undergo a mesenchymal to epithelial transition (MET) after
extravasation in distant organs to form overt (macro)metastases
[10,11].
The highly complex process of EMT is busily studied at the
molecular level. It appears that EMT (and potentially with it metas-
tasis) does not rely on additional genetic alterations in the cancer
cells. Rather complex regulatory circuits involving transcriptional
and epigenetic control mediated by distinct ‘‘EMT’’ transcription
factors, miRNAs and lncRNAs seem to govern an EMT [8,12,13].
Despite or because of the recent insights, it is worthwhile to take
a step back and ask to what extent signs of an EMT are detected
in primary tumors, whether an EMT is actually required in the pro-
cess of metastasis, and to discuss potential alternative models of
cancer cell dissemination. Here, we focus on breast cancer, since
this cancer type is frequently studied in metastasis research,
mainly due to the availability of a variety of valuable transgenic
and transplantation mouse models of metastatic breast cancer
[14]. In addition, based on the recent molecular classiﬁcations of
breast cancer subtypes and the identiﬁcation of a claudin-low sub-
type exhibiting an EMT gene expression signature, breast cancer
speciﬁcally qualiﬁes to assess the role of EMT in the metastatic
process [15].
Fig. 1. The potential involvement of EMT and MET in the metastatic cascade. Carcinoma cells reach the systemic circulation by collective invasion (1) or single-cell migration
of EMT-derived mesenchymal cells (2) into the blood vessels. Alternatively, they can be passively shed (3) into the blood stream. Circulating tumor cells (CTC), either single
cells or CTC-clusters, are found to express predominantly a spectrum of epithelial markers (E), co-express epithelial and mesenchymal markers (E/M) or to express
predominantly mesenchymal markers (M; 4). CTCs are frequently covered by platelets, facilitating carcinoma cell extravasation. At distant organ sites, surviving CTCs are
potentially extravasating similar to leukocytes by initial transient contacts, followed by ﬁrm adhesion to endothelial cells and subsequent diapedesis and active extravasation,
although direct proof for this multistep mechanism is still lacking (5). CTCs are also physically trapped due to size restriction in small vessels and initiate proliferation inside
the vessel lumen (6). In order to colonize, i.e. to grow from micro- to macrometastases, mesenchymal carcinoma cells may need to undergo an MET (7). The hematogenous
spread of breast cancer cells displays speciﬁc tropism to lung, brain, liver and bone.
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Carcinomas, i.e. malignant cancers of epithelial origin, often
retain – until a certain state of dedifferentiation – a sheet-like mor-
phology with apico-basal polarity and intact tight and adherens
junctions. A prototypical EMT of these cells involves a spectrum
of processes having in common the loss of apico-basal polarity
and the delocalization of tight and adherens junction proteins,
such as E-cadherin, ZO-1, occludins, and claudins. At the same
time, they assume a spindle-shaped, mesenchymal-like morphol-
ogy with upregulated expression of mesenchymal markers, such
as N-cadherin, ﬁbronectin and vimentin, and increased migratory
and invasive properties [16]. EMT can be easily induced in breast
cancer cells in 2D in vitro culture, for example by transforming
growth factor (TGFb) or the overexpression of EMT-inducing tran-
scription factors such as TWIST. In addition, EMT-associated migra-
tory and invasive capacities can conveniently be studied in vitro by
quantifying the efﬁciency of cells to migrate through porous mem-
branes, either uncoated (for migration) or coated with a layer of
extracellular matrix proteins (for invasion) [17,18]. Although this
reductionist approach has provided major mechanistic insights
into the principles of EMT and cell invasion, the results cannot be
simply extrapolated to the in vivo situation in animal models or
in patients [19–22]. Studying EMT in vivo mostly relies on a retro-
spective, ‘‘snapshot’’ analysis of surrogate markers for cell migra-
tion and invasion and thus lacks critical information on the
dynamic changes underlying an EMT process. Migration and inva-
sion per se can only be visualized by technically challenging
intra-vital life cell imaging techniques in 3D matrices and in living
animals [23–25].3. Cell migration, invasion and intravasation
3.1. Individual cell migration
Tumor cells migrate either as single cells (individual migration)
or as multicellular groups (collective migration) [26,27]. The char-
acteristics of a special type of cell migration, where cells are
aligned in single-cell chains in so called ‘‘indian ﬁles’’, will be pre-
sented below when discussing the relation of EMT to the lobular
histopathologic subtype of breast cancer [21]. Individually migrat-
ing cells usually employ mesenchymal traits of migration with
integrin-mediated cell–extracellular matrix (ECM) adhesion
dynamics characterized by the generation of high traction forces,
the use of proteases for ECM cleavage and the formation of focal
contacts at sites of integrin clustering [21]. As an alternative, can-
cer cells may ‘‘squeeze’’ through tissues by amoeboid migration,
which is characterized by propulsive cytoplasmic forward ﬂow,
the lack of integrin-ECM contacts and the absence of proteolytic
cleavage of the ECM. Notably, amoeboid migration is substantially
faster than mesenchymal migration [28–30]. In addition, a hybrid
amoeboid/mesenchymal phenotype of cancer cells has been
described [31]. In a seminal study, the Sixt laboratory has demon-
strated that murine leukocytes, which usually utilize
integrin-mediated contacts to move on 2D surfaces, do not depend
on adhesion to the ECM via integrins when migrating through a 3D
environment in an amoeboid-like fashion [32]. In line with this
ﬁnding, blockade of integrin function induces a so-called mes-
enchymal to amoeboid transition (MAT) even in cancer cells of
solid tumors [33,34]. Cells induced to undergo an EMT by TGFb also
switch to a faster amoeboid migration mode in experimental
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[28]. Numerous MAT-inducing mechanisms have been identiﬁed in
the past years, including inhibition of ECM-degrading proteases or
of Rac1 activity, induction of RhoA activity, the forced expression of
EphA2 or p27, and p53 deﬁciency [21,35–40]. These reports may
explain why anti-cancer therapies targeting protease or integrin
functions have shown disappointing results in clinical trials [40–
43].
A novel mechanism of cell extrusion has been recently proposed
by which epithelial cells may leave the epithelial sheet [44]. In nor-
mal epithelial tissue homeostasis, dying cells are actively extruded
apically into the lumen to preserve a tight barrier function. In con-
trast, oncogenic signaling in transformed cells leads to a basal
extrusion of cancer cells. Since in some circumstances cancer cells
can cross basement membranes (BM) without proteolytic degrada-
tion, basally extruded cancer cells might not necessarily leave
behind a BM defect [26,44–47]. Whether a basal extrusion process
plays a role in cancer cell dissemination and whether there is func-
tional connection with an EMT will be part of exciting future
research [44].
3.2. Collective cell migration
Collective cell migration is characterized by the simultaneous
movement of a group of cells with intact cell–cell interactions.
Depending on their morphological appearance, these collectives
can be classiﬁed into ‘‘clusters’’, ‘‘strands’’, ‘‘tubes’’ or ‘‘sheets’’
[48]. Collective cell migration is proposed to be a predominant
mode of local cancer cell invasion especially in differentiated carci-
noma [49]. Leader cells guide the multicellular aggregate by prote-
olytic degradation of the ECM in the front and by dragging the cells
of the inner and trailing edge. Since the leader cells appear to play a
dominant role in the movement of these collectives, their charac-
teristics warrant attention – also in relation to EMT. Notably, the
importance of a basal epithelial program in the invasive phenotype
of locally invading breast cancer has been reported [49]. Leader
cells express basal epithelial markers, such as cytokeratin 14 and
p63, while lacking evidence for EMT-associated features, such as
the loss of E-cadherin function or increased TWIST, SNAIL or
vimentin expression. Although a complete EMT seems not obvious
in cells leading collectively invading multicellular groups, this does
not exclude a sub-threshold level EMT or intermittent bursts of
EMT, as earlier discussed by Friedl and colleagues [26]. In addition
to the perception that collective migration is used by epithelial
cancer cells, it is also employed by mesenchymal cancer cells
[23,50–52]. In mesenchymal cells, cell–cell contacts are mediated
by N-cadherin, a cadherin family member characteristic of a mes-
enchymal cell phenotype [51,53].
Similar to what has been described for plasticity of individually
migrating cells, collectively migrating cells can eventually leave
the group and continue their march individually, by either migrat-
ing in a mesenchymal or in an amoeboid mode – the latter is
known as collective to amoeboid transition (CAT). Fibrosarcoma
and melanoma cell lines preferentially use collective migration in
3D collagen densities (smaller ECM pore sizes), whereas lower col-
lagen densities (bigger ECM pore sizes) induce the break-out of sin-
gle cells [23], and blocking b1-integrin induces a CAT in primary
melanoma explants [50].
3.3. Cancer cell intravasation
Cancer cells can actively enter the systemic circulation
employing the migration and invasion modes described above.
However, one should be aware of the fact that cancer cells arepassively shed into the blood stream at impressively high num-
bers [54–58]. In addition, not only ‘‘how’’ but also ‘‘where’’ cancer
cells enter the blood circulation matters. Most investigations and
deliberations on the mechanisms of cancer cell invasion, as indi-
vidually or collectively migrating cells, are focusing on the inva-
sive front, i.e. the zone of direct contact between the tumor
cells and the surrounding desmoplastic stroma [59]. However,
tumor cells can disseminate at the stage of carcinoma in situ as
proposed by the parallel progression model possibly even before
the occurrence of an angiogenic switch [60]. The signiﬁcance of
the invasive front might therefore primarily be a surrogate of
the intrinsic invasive capacity of a tumor plus having a causal
role in the loco-regional spread of cancer cells. On the other hand,
tumors are highly vascularized and contain a ‘‘highway’’ of
hematogenous spread inside the tumor mass. Indeed, intra-vital
imaging has visualized the intravasation of tumor cells within
the tumor mass [61]. Interestingly, an EMT drives the expression
of a set of pro-angiogenic genes, partially explaining the
enhanced tumor-initiating capacity often associated with the
EMT process [62,63]. Based on these ﬁndings it appears that an
EMT not only renders tumor cells more capable of migrating
toward close-by blood vessels, but their pro-angiogenic activities
may enable them to ‘‘path their own way’’ into the systemic
circulation.
The possibility of switching between different types of cell
migration illustrates the large plasticity of cancer cells and the
complexity of their therapeutic targeting. The molecular mecha-
nism underlying the different types of cancer cell migration, the
conversion between these different types, the environmental fac-
tors promoting this transitions, and the characteristics of the sub-
sets of cells of a given tumor that hold this plasticity still need to be
further elucidated. The different modes of cell migration do not
seem to be mutually exclusive for a given cell. In a ‘‘tuning model’’,
the mode of cell migration is characterized as a continuum and is
the result of the integration of physical and biochemical inﬂuences
of the tissue environment with the genetic and epigenetic makeup
of a given cell [48]. Given the emerging picture of intra-tumoral
heterogeneity in cancer [64,65], it is likely that different areas
within an individual tumor rely on distinct modes of cell migration
and invasion.
4. Does an EMT occur in primary tumors?
Carcinomas often elicit a desmoplastic reaction with abundant
mesenchymal stroma cells, such as cancer-associated ﬁbroblasts,
with predominantly pro-tumorigenic activities [66]. Conventional
histopathological analysis can conveniently discriminate between
epithelial cancer cells and ﬁbroblasts with their prototypical
spindle-shaped morphology. However, once epithelial cancer cells
have converted to a mesenchymal morphology by an EMT, they are
hardly distinguishable from stromal ﬁbroblasts. Also the marker
repertoire of cancer cells changes to a mesenchymal phenotype
after undergoing an EMT and, thus, mesenchymal carcinoma cells
remain indistinguishable from stromal ﬁbroblasts by molecular
or immunohistochemical analyses. Notably, the expression of
cytokeratins or epithelial cell adhesion molecules such as EpCAM,
which are routinely used to identify tumor cells of epithelial origin,
is lost during an EMT [67]. In this context it also should be noted
that, in contrast to early embryonic developmental processes, the
concept of EMT in malignant tumor progression reﬂects a transi-
tion within the same lineage and does not signify a real conversion
of cells of an epithelial lineage to a mesenchymal lineage – a dis-
tinction that has brought some controversy into the discussion
about the existence of EMT in cancer [22,68].
1580 R. Bill, G. Christofori / FEBS Letters 589 (2015) 1577–15874.1. EMT in preclinical breast cancer mouse models
Syngeneic and xenogeneic transplantation models of breast
cancer cell lines in mice have been extensively used in order to
establish a causal relationship between EMT and metastatic dis-
semination by interfering with critical mediators of EMT, including
EMT-inducing growth factor signaling or transcription factor activ-
ities [2]. Although transplantation models of primary cancer cells
and established cancer cell lines offer important mechanistic
insights into the metastatic cascade, there value is limited by the
lack of a slow co-evolution of the implanted cancer cells with the
host stroma. In the case of xenografts, the differentiation state of
the cells lines used, the lack of an intact immune response, and
potential species incompatibilities of growth factor signaling may
obscure the processes active in patients [69]. For example, the
human breast cancer cell line MDA-MB-231, a frequently used
xenograft metastasis mouse model, stably displays mesenchymal
traits at baseline, which limits the study of the dynamic processes
of an EMT [70]. Hence, to delineate a possible causal role of EMT in
breast cancer metastasis we will focus on data derived from trans-
genic mouse models of breast cancer.
In transgenic mouse models of breast cancer, ﬁrst
lineage-tracing experiments have provided evidence that EMT
exists in vivo. By genetically tagging tumor cells combined with
immunoﬂuorescence analysis of marker expression, Trimboli and
colleagues identiﬁed carcinoma cells with a loss of E-cadherin and
gain of ﬁbronectin expression. Interestingly however, carcinoma
cells with signs of EMTwere only detected in a c-MYC-driven trans-
genicmousemodel of breast cancer and not in theMMTV-PyMT and
MMTV-Neu transgenic mouse models of breast cancer, which are
two widely used models to study breast cancer metastasis [71]. In
contrast, phospho-SMAD2 and phospho-SMAD3 have been identi-
ﬁed in certain areas of MMTV-PyMT tumors as an indicator of active
TGFb signaling, yet the EMT marker status of these tumors has not
been assessed [72,73]. The conditional deletion of p53 in mammary
epithelial cells of mice (achieved by Cre recombinase expression
under the control of the K14 or WAP promoters, respectively) pro-
voked the formation of some tumorswith carcinosarcomatousmor-
phology, with heterogeneous expression for the luminal marker
cytokeratin 8 and the basal marker cytokeratin 14, and with
increased vimentin expression. Yet, despite the invasive phenotype
of the tumors, distant metastasis is a rare event in these models
[74,75]. When CRIPTO-1, a member of the epidermal growth
factor-CFC protein family, was conditionally overexpressed in
mammary epithelial cells, tumors eventually developed with a
latency of 14–18 months in a proportion of multiparous mice.
Whereasmost lesions displayed a differentiatedmorphology classi-
ﬁed as papillary adenocarcinomas, some tumors contained areas
with an EMT phenotype (negative for E-cadherin and positive for
N-cadherin, ﬁbronectin, a-smooth muscle actin, vimentin, and
SNAIL) [76]. Similarly, conditional overexpression in the adult
mammary epithelium of the sine oculis homeobox 1 homolog
(SIX1) homeoprotein led to tumors of a variety of different grades
of differentiation [77]. A subset of the tumors displayed a sarcoma-
toid phenotypewith the expression of markers suggestive of a com-
plete EMT. In addition, 80% of the non-sarcomatoid tumors showed
a partial EMT with areas of E-cadherin loss and nuclear b-catenin
accumulation colocalizing with high expression of the Wnt target
gene cyclin D1.
For a reality check as to whether transgenic mouse models of
breast cancer faithfully recapitulate the patient situation, gene
expression proﬁles of the model tumors have been compared to
the gene expression of the various patient breast cancer subtypes
(see also below). Whereas tumors of a variety of mouse models dis-
played a ‘‘luminal-like’’ gene expression proﬁle (the majority of
tumors from MMTV-PyMT, MMTV-Neu and WAP-Myc mice), aproportion of model tumors showed either strong expression of
mesenchymal features or mixed expression of luminal, basal and
mesenchymal signatures (tumors from Brca1ﬂ/ﬂ;TgMMTV-Cre;p
53+/, WAP-Myc, or DMBA-treated mice) [15].
Taken together, there is convincing evidence that tumor cells
bearing a mesenchymal phenotype exist in primary tumors of
transgenic mouse models of breast cancer. To assess whether even
rare cells with mesenchymal features, which are unable to signiﬁ-
cantly inﬂuence the global gene expression proﬁle of the bulk of a
tumor, are present in the metastatic mouse models of breast can-
cer, appropriate lineage-tracing experiments need to be performed.
Such genetic fate mapping of tumor cells combined with
immunoﬂuorescence staining for mesenchymal markers has
recently identiﬁed an EMT as a very early event in a pancreatic
ductal adenocarcinoma mouse model [78].4.2. Mechanisms of EMT in mouse models of breast cancer
It is important to note that any evidence for an EMT in a pri-
mary tumor does not necessarily allow the conclusion that an
EMT is a prerequisite for the metastatic process. To this end, func-
tional studies are needed in which ‘‘key EMT players’’ are geneti-
cally manipulated in transgenic mouse models of breast cancer.
Subsequent characterization of changes in EMT marker expression
in primary tumors and metastatic lesions, the assessment of pri-
mary tumor grade and local invasiveness as well as the metastatic
burden (typically in the lung) reveals the functional roles of factors
of interest in EMT and/or metastasis. Candidates to be assessed
could be EMT-inducing cytokines, such as TGFb, EGF, FGF, and
HGF, hypoxia induced by rapid tumor growth or by the pharmaco-
logical inhibition of blood vessel angiogenesis (anti-angiogenic
therapies), components important for cell–cell contact and cell
polarity, and EMT-inducing transcription factors, such as TWIST,
SNAIL1/2, and ZEB1/2 [2,16]. Exciting insights have already been
obtained by studying the tumor-promoting role of TGFb and some
of the transcription factors relevant for EMT (see below), yet fur-
ther studies are needed to identify and distinguish between ‘‘sim-
ple’’ markers of an EMT in vivo and factors with non-redundant
functions during an EMT.
TGFb, one of the best-studied EMT-inducing cytokines, is pro-
duced by both tumor cells and by a variety of cells of the tumor
microenvironment. It exerts important effects on several cell types
within a tumor and by canonical, SMAD-dependent and
non-canonical, SMAD-independent signaling modulates the
expression of a variety of target genes to either exert tumor sup-
pressive functions, such as induction of the cell cycle inhibitor
p21 or repression of c-MYC, or tumor-promoting functions by
inducing an EMT (for a detailed description of TGFb signaling and
its role in cancer see reference [79]). Consistent with this notion,
MMTV promoter-driven mammary epithelial cell-speciﬁc expres-
sion of TGFb in the MMTV-Neu model results in primary tumors
with higher tumor grades and increased metastatic burden in the
lungs. Interestingly, despite the TGFb-mediated increased local
invasiveness, primary tumors still express E-cadherin and do not
upregulate the mesenchymal markers vimentin, alpha-SMA and
ﬁbronectin [80]. Similarly, overexpression of TGFb in
MMTV-PyMT transgenic mice at late stages of tumor development
dramatically increases metastasis to the lungs [81]. In line with the
pro-metastatic activities of TGFb in the MMTV-Neu driven breast
cancer mouse model, expression of a constitutive–active TGFbRI
promotes the metastatic process, whereas expression of a
dominant-negative TGFbRII inhibits lung metastasis [82,83].
Notably, one of these studies has revealed an important role of
TGFb signaling for tumor cell extravasation rather than for primary
tumor invasion and tumor cell intravasation [83].
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experiments where neutralization of TGFb by a soluble TGFbRII:Fc
fusion trap has reduced the incidence of lung metastasis in
MMTV-Neu and MMTV-PyMT mice [84]. Since the TGFbRII:Fc trap
reduced the number of colony-forming circulating tumor cells
(CTCs), the authors suggested a role for TGFb in intravasation.
Alternatively however, CTCs could also come from growing metas-
tases, and the reduction in CTCs may simply reﬂect the lower
metastatic burden. In contrast to these reports, the Moses labora-
tory has reported a metastasis-promoting effect when attenuating
TGFb signaling in the MMTV-PyMT and MMTV-Neu models by a
tumor cell-speciﬁc deletion of TGFbRII or the expression of a
dominant-negative TGFbRII, respectively [72,85]. Mechanistically,
abrogation of TGFb signaling in the MMTV-PyMT model results
in the recruitment of Gr1+CD11b+ myeloid-derived suppressor
cells, which by secreting MMPs promote invasion of
E-cadherin-positive tumor cells [86]. In TGFb-attenuated
MMTV-Neu tumors, increased VEGF-A expression provokes leaky
vessels and potentially facilitates cancer cell intravasation [85].
Based on TGFb’s context-dependent and highly complex impact
on tumor cells and on cells of the tumor microenvironment, it is
not surprising that manipulation of the different components of
the TGFb/TGFR signaling axis leads to a wide range of sometimes
contradictory effects on metastasis formation.
Employing the Rip1Tag2 transgenic mouse model of neuroen-
docrine carcinoma of the pancreas we have previously shown that
abolition of E-cadherin (Cdh1)-mediated cell–cell adhesions can be
a trigger of tumor invasion and metastasis [87]. Derksen and
co-workers have recently reported that the concomitant genetic
ablation of Cdh1 and Trp53 in mammary epithelial cells of the
mouse induces the formation of invasive and metastatic lobular
breast carcinomas which, however, do not display features of a
complete EMT [74,75]. These data suggest that, although loss of
E-cadherin is sufﬁcient to induce local invasion and distant metas-
tasis, it does not necessarily promote a complete EMT – in contrast
to what is observed in cell culture experiments [88,89]. A charac-
teristic molecular event observed during an EMT is the transcrip-
tional shut-off of the Cdh1 gene by EMT-inducing transcriptional
repressors, such as SNAIL1/2, TWIST1/2, and ZEB1/2 [16].
Accordingly, the inducible expression of TWIST1 and with it the
induction of an EMT in the primary tumor site allows the dissem-
ination of tumor cells to distant organs. However, metastatic out-
growth at the distant organs requires the loss of TWIST1
expression and a mesenchymal-to-epithelial transition (MET; see
below; [90]). In a mouse model of invasive mammary carcinoma
with doxycycline-inducible expression of a constitutive–active
version of the Her2/Neu (NeuNT) oncogene, NeuNT-driven tumors
completely regress after doxycycline withdrawal and oncogene
expression shutdown, yet they display NeuNT-independent recur-
rence after a latency of several months [91]. Whereas tumors
occurring during the initial NeuNT-driven growth phase show
extensive lung metastasis but retain an epithelial morphology,
the recurring tumors display a SNAIL1-driven mesenchymal phe-
notype with downregulation of CK8 and E-cadherin and upregula-
tion of vimentin and ﬁbronectin expression. Indeed, the
experimental manipulation of a variety of EMT-relevant genes,
such as the genes encoding for SNAIL1/2, TWIST1/2, ZEB1/2,
FOXC2, SOX4, TEAD2, LHX2, and others, results in a change in
breast cancer cell invasion and dissemination and in metastasis
formation, evidencing a link between EMT and the disseminating
and tumor-initiating capabilities of carcinoma cells (reviewed in
[16,92,93]). However, a formal proof that metastases are indeed
initiated by cancer cells that have ever undergone an EMT is still
lacking and will require sophisticated fate-mapping experiments
in animal models.5. Extravasation, MET and colonization
5.1. Extravasation
Disseminating cancer cells, after having survived the harsh con-
ditions of their travel through the blood stream, have in principle
two possibilities how they can form a metastatic nodule in a dis-
tant organ: physical trapping in small capillaries of the target
organ due to size restriction and initial proliferation inside the vas-
cular lumen and subsequent disruption of the vessel wall as the
metastasis expands [94], or extravasation and subsequent prolifer-
ation in the extra-luminal compartment. While the former is difﬁ-
cult to address experimentally without sophisticated intra-vital
imaging, the latter is supported by ﬁrst experimental evidence:
similar to the behavior of leukocytes when egressing from blood
vessels at inﬂammatory sites by binding to selectins and subse-
quent ﬁrm adhesion via integrins (tethering, rolling), cancer cells
are able to establish weak contacts with endothelial cells in vitro
[95]. However, in vivo evidence for the existence of such initial
weak contacts is still missing [96]. Stable contacts of tumor cells
to endothelial cells seem to be mediated by adhesion molecules
such as members of the integrin-family and CD44 and
N-cadherin [96,97]. Several of these molecules with important
functions during transendothelial migration (TEM) are upregulated
during an EMT. For example, increased N-cadherin expression and
the loss of E-cadherin expression, the cadherin switch, is one hall-
mark of an EMT [53]. Moreover, EMT-induced integrins on cancer
cells can interact with cell adhesion molecules (CAMs) expressed
by endothelial cells. Finally, an EMT often leads to the upregulation
of enzymes that modify carbohydrate moieties on selectin-binding
glycoproteins. On one hand, CD44 isoforms with speciﬁc glycosy-
lated residues have been described to mediate initial weak con-
tacts by binding to E-selectin expressed by endothelial cells,
whereas on the other hand CD44 plays an important role by medi-
ating ﬁrm adhesion to endothelial cells [96]. Notably, human
breast cancer cells that have undergone an EMT and resemble
breast cancer stem cells are characterized by the expression of high
levels of CD44 [98]. In addition, upregulation of TGFb and VEGF-A
by an EMT can enhance permeability of the capillary bed and
thereby promote TEM [99,100]. Hence, the pro-angiogenic pheno-
type of cancer cells acquired during an EMT does not only promote
intravasation by creating a disorganized vessel network in the pri-
mary tumor but also may facilitate extravasation at distant sites.
The extravasation process involves a crosstalk between the cancer
cells and endothelial cells, and leukocytes, platelets and proteins of
the coagulation cascade play supportive roles [7,101]. For example,
platelets frequently embrace circulating tumor cells and, by releas-
ing TGFb, they induce an EMT of cancer cells inside the blood
stream and thus increase their extravasation into the lung [7].
Amoeboid cell migration of cancer cells, on the other hand, has also
been shown to promote TEM [102]. However, the spatial and tem-
poral contribution of the mesenchymal vs. the amoeboid pheno-
type during the process of TEM and subsequent crossing of the
underlining basement membrane during the process of cancer cell
extravasation in vivo has to be further investigated.
5.2. MET and colonization
If EMT plays an important role in metastasis formation, how
comes that carcinoma metastases frequently display a similar
degree of differentiation as the primary tumor [11]? One formal
possibility has it that EMT is dispensable for intravasation, and
cancer cells rather intravasate by collective migration of epithelial
cell clusters or by passive shedding into the circulation, promoted
by the disorganized and leaky vasculature present in the primary
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EMT is a transient/dynamic process conferring high plasticity to
cancer cells. Thereby it has been postulated that EMT-derived mes-
enchymal cells, which are thought to be slowly proliferating cells
with cancer stem cell-like properties, are forced to undergo a mes-
enchymal to epithelial transition (MET) to be able to initiate prolif-
eration [11]. If so, what triggers an MET? Is it simply the lack of
EMT-inducing factors in the inhospitable environment of meta-
static target organs, or are distinct factors actively promoting MET?
There is a plethora of experimental evidence, supporting the
hypothesis that MET in the target organ is required for coloniza-
tion. One of the earliest reports about the requirement for MET
during metastatic outgrowth comes from experiments with a
human bladder carcinoma cell line, which by serial passaging in
mice gave rise to subclones with increased metastatic potential.
Whereas the parental cell line displayed mesenchymal features,
the higher metastatic subclones were of epithelial morphology
and expressed epithelial markers. However, in contrast to these
results by intracardial injection, when the cells were injected
orthotopically and all steps of the metastasis cascade had to be
successfully completed to form metastases, the mesenchymal par-
ental cell line has shown higher metastatic potential than the
epithelial subclones. These results raise the possibility that an
EMT plays a critical role in the early steps and an MET in the late
steps of the metastatic cascade. Mechanistically, MET can be pro-
moted by increased FGFR2 expression, interestingly by the
mesenchymal-speciﬁc splice isoform FGFR2IIIc [104]. In line with
these ﬁndings, cells isolated from lung metastases of
patient-derived breast cancer xenograft mice (PDX mice) of the
basal-like subtype partially lose their aggressiveness compared to
the parental tumor cells, accompanied by a more differentiated,
MET-like status [105]. A requirement for MET in lung colonization
has been further demonstrated by spatially restricting TWIST1
expression to the primary tumor site and preventing its expression
during the lung colonization process [90] or by reducing the
expression of the EMT-inducing transcription factor PRRX1 [106].
Along these lines, mesenchymal, E-cadherin-deﬁcient breast can-
cer cells derived from the MMTV-Neu mouse model seed more
lung metastases upon orthotopic mammary fat pad injection as
compared to epithelial, E-cadherin-expressing cells. However,
mesenchymal, E-cadherin-deﬁcient cells are less metastatic as
compared to the epithelial cells when injected into the tail vein
[62], again supporting a critical role of an EMT in the early and
of an MET in the late stages of metastasis formation. Although
TGFb is a well-characterized inducer of EMT, a recent report has
proposed that TGFb can also induce MET in mesenchymal cancer
cells via induction of ID1, which in a dominant-negative manner
inhibits TWIST1 activity and increases stem cell-like features of
the cells [107]. The same publication proposes the existence of
both epithelial and mesenchymal cancer cells with
tumor-initiating properties. Indeed, two distinct populations of
cancer cells in primary breast cancer patient samples have been
identiﬁed: an epithelial cell population expressing the enzyme
aldehyde dehydrogenase and a mesenchymal cell population char-
acterized as CD44+ CD24 [108]. In contrast to the reports above
underlining the importance of MET in metastatic colonization,
recent work has demonstrated that a mesenchymal phenotype
with increased b1 integrin and focal adhesion (FAK) activity and
increased ﬁlopodia formation promotes active lung colonization
and metastatic outgrowth of breast cancer cells [95,109].
Moreover, overexpression of a constitutive–active form of the
EMT-inducing transcription factor TEAD2 promotes rather than
inhibits lung metastasis formation upon i.v. injection of murine
breast cancer cells [92]. Apparently, the ﬁne-tuned cell plasticity
and the functional interplay between EMT in earlier stages andMET in the later stages of the metastatic cascade warrants further
investigation.
6. Evidence for EMT in human breast cancers
Breast cancers do not represent a single cancer entity but
instead summarize a broad spectrum of different malignant dis-
eases of the breast. Several classiﬁcation systems are employed
in order to provide the optimal treatment regiment for breast can-
cer patients. Traditionally – and still of great value – breast cancers
have been classiﬁed according to their morphologic appearance
into several histological types. Secondly, immunohistochemical
analysis of the estrogen receptors (ER) and progesterone receptors
(PR) as well as HER2 expression stratiﬁes patients to
anti-hormonal therapy and therapeutics targeting HER2. Since
the beginning of this millennium, a new layer of classiﬁcation
has been achieved by the use of gene expression proﬁling
[110,111].
In the early days, pathologists have developed and employed a
highly sophisticated classiﬁcation system for malignant diseases of
the breast based on cancer (cell) morphology. Most invasive breast
cancer patients are diagnosed with invasive breast carcinoma of no
special type (previously termed invasive ductal carcinoma) [112].
Two less frequently observed subtypes, which are interesting with
regards to EMT, are invasive lobular carcinoma and metaplastic car-
cinoma. Invasive lobular carcinoma cells can migrate as so-called
‘‘indian ﬁles’’, which is regarded as a single-cell migration mode,
although the cells are in close contact to each other at their front
and rear [27]. One hallmark of invasive lobular carcinoma is the
mutation or reduced expression of E-cadherin. Interestingly, based
on gene expression analysis, these tumors were highly prevalent in
the luminal A subtype, which is usually characterized by its
well-differentiated epithelial morphology [113]. These data,
together with the results from the E-cadherin-deﬁcient mouse
models of lobular breast carcinoma discussed above [75], contra-
dict the results from in vitro experiments demonstrating that a loss
of E-cadherin function is sufﬁcient to induce a complete EMT
[62,89].
Metaplastic carcinomas represent – among others – tumors with
mesenchymal phenotype and they are typically negative for ER, PR
and HER2 expression (i.e. triple-negative). For the nomenclature of
the mesenchymal representatives of this subtypes, the terms carci-
nosarcoma and sarcomatoid carcinoma are often used as syn-
onyms. Interestingly, metaplastic carcinomas are often classiﬁed
as basal-like or claudin-low (identiﬁed based on an EMT-like gene
expression signature, see below), they frequently carry mutations
of TRP53 and generally respond less to chemotherapy than other
triple-negative breast cancers [70,114]. Regarding the etiology of
their mesenchymal appearance, it is currently unclear if this is
due to epigenetic (potentially reversible EMT) or genetic (irre-
versible EMT) alterations. Other than that, using the term of an
EMT to describe the etiology of their mesenchymal morphology
implies an epithelial cell as origin, a notion that currently lacks
experimental support.
The advent of gene expression proﬁling has revolutionized the
classiﬁcation systems of cancer in general and of breast cancer in
particular and has revealed functional insights into the biological
processes underlying breast cancer morphology. Based on gene
expression proﬁling, invasive breast cancers were initially classi-
ﬁed into the intrinsic subtypes luminal A, luminal B,
HER2-enriched basal-like, and normal breast-like [110,115]. Later
on, these categories were extended by the claudin-low subtype,
which with regard to EMT warrants further attention [15,70].
The claudin-low breast cancer subtype is characterized by the
low expression of epithelial markers (E-cadherin, occludin, claudin
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receptors ER, PR, HER2 (triple-negative). It is distinct from the clo-
sely related triple-negative, basal-like subtype – besides the
enrichment of an EMT gene expression signature – by lower
expression of proliferation genes [70]. On the other hand,
claudin-low tumors display increased expression of genes involved
in angiogenesis, cell migration, immune system response (i.e.
CXCL12) and extracellular matrix (vimentin), to name but a few.
Overall, the gene expression proﬁle of claudin-low tumors suggests
an EMT phenotype with a signiﬁcant amount of different inﬁltrat-
ing leukocytes [70]. Importantly, several studies have shown that
tumors of the claudin-low, but not of the basal-like subtype, are
enriched in cancer stem cell/tumor-initiating cell signatures, which
is consistent with the ﬁnding that EMT and tumor-initiating prop-
erties are often shared [1,70]. Regarding their histopathological
appearance, of the tumors classifying as claudin-low most of them
classify as invasive carcinomas not otherwise speciﬁed, while only a
minority is characterized as metaplastic or medullary carcinoma
[70].
If EMT plays an essential role in the process of leaving the pri-
mary tumor and entering the systemic circulation, one would
assume that the higher the percentage of cells with an EMT pheno-
type in the primary tumor is, the higher the likelihood of distant
metastasis and shorter patient survival will be. However, an EMT
signature does not predict breast cancer patient survival [116].
Moreover, claudin-low tumors do not show a worse prognosis than
luminal B, HER2-enriched or basal-like – the other subtypes with
poor prognosis [70]. These results are rather surprising, since it
has been shown for many individual key EMT players, including
FOXC1, SOX4, LXH2, PRRX1, and for a signature composed of
TGFb-pathway components and downstream targets that their
high expression correlates with poor clinical outcome
[5,93,106,116,117]. An association between lung metastasis
relapse and an enrichment of a TGFb-response signature has only
been found in ER primary breast tumors but not in ER+ breast
tumors, and this signature is not prognostic for metastatic relapse
in the liver, bone and brain [100]. In contrast to the lack of prog-
nostic impact on patient survival, several reports have linked
tumors of the claudin-low subtype with resistance to chemother-
apy, in concordance with the general assumption that cells with
an EMT phenotype are intrinsically more refractory to chemother-
apy [118]. Along these lines, a gene expression signature repre-
senting stromal cells or mesenchymal tumor cells has been
associated with a poor response to neoadjuvant chemotherapy
[119]. In addition, claudin-low tumors have shown to be less
chemosensitive than basal-like tumors [70], and a pathological
complete response has been negatively correlated with an EMT sig-
nature [116]. Intriguingly, the claudin-low and a cancer stem cell
signature are enriched after neoadjuvant treatment with endocrine
therapy or chemotherapy compared to pre-treatment conditions
[120]. Taken together, it appears that the claudin-low signature
per se is not an indicator of poor prognosis compared to other
aggressive intrinsic breast cancer subtypes, but it seems to be pre-
dictive for inferior response to therapy.
Many question remain. For example, similar to the case of
metaplastic tumors discussed above, why do certain breast tumors
display a mesenchymal gene expression proﬁle? Is it due to geno-
mic alterations resulting in an irreversible EMT or is it rather due to
less stable epigenetic marks or constant EMT-inducing signals of
the surrounding tumor stroma? In addition, if the cell of origin of
claudin-low tumors is found within the mammary stem cell com-
partment, the term EMT may be misleading, since the cell of origin
never has achieved an epithelial differentiation [121,122].
Global gene expression proﬁling of breast cancer samples has
critically contributed to the understanding of inter-tumoral
heterogeneity; it has provided important information about thepredominant intrinsic breast cancer subtypes in the sample ana-
lyzed. However, it does not account for the potential co-existence
of different tumor cell subpopulations – i.e. intra-tumoral hetero-
geneity [70]. Apparently, industrious single cell analysis seems
required to address the extent and quality of tumor heterogeneity
in breast cancer.
To potentially detect rare cancer cells with an EMT phenotype,
immunostainings of tumor sections with antibodies against
epithelial and mesenchymal markers have been performed. The
technical hurdle to distinguish stromal cells from mesenchymal
tumor cells in human tumors has recently been elegantly circum-
vented by performing RNA in situ hybridizations (RNA-ISH) on
HER2-positive primary breast cancer patient samples concomi-
tantly against HER2 – to identify tumor cells – and against a collec-
tion of mesenchymal markers [123]. This approach identiﬁed
tumor cells expressing mesenchymal markers in these primary
tumor samples. In the same study, by using dual-colorimetric
RNA-ISH against a pool of epithelial transcripts and a pool of mes-
enchymal transcripts, they identiﬁed biphenotypic cells
co-expressing both epithelial and mesenchymal markers in pri-
mary breast cancer samples – interestingly, not necessarily at the
invasive front – and in draining lymph nodes. Strikingly, the high-
est percentage of epithelial and mesenchymal double-positive
tumor cells is found in the triple-negative subtype known to dis-
play a particularly aggressive clinical course [123]. Similarly, it
has been reported that cells co-expressing epithelial and mes-
enchymal markers are predominantly observed in samples of
claudin-low and basal-like tumors [70,124]. These ﬁndings clearly
show that ‘‘partial EMT’’ (i.e. the co-expression of epithelial and
mesenchymal markers) can be observed by histopathological anal-
ysis of human breast cancer tissue. Hence, a complete EMT might
not be a prerequisite for tumor cell dissemination, consistent with
the observation that partial EMT represents a state with higher cell
plasticity than a complete EMT [125]. Whether cells with a com-
plete EMT can be identiﬁed within the bulk of cancer-associated
ﬁbroblasts (CAFs) within the tumor stroma remains unclear.
While tumor cell-speciﬁc genetic alterations can be found in stro-
mal cells of breast cancers [126,127], clonal somatic genetic alter-
ations have not been found in CAFs isolated from breast and
ovarian cancer stroma [128].7. Lessons learned from circulating tumor cells (CTCs)
The prototypical role of EMT in cancer progression is often
described as the initial process of the metastasis cascade, i.e. the
gain of migratory and invasive properties allowing cancer cells to
leave the primary tumor, to invade into nearby blood vessels and
to access the blood circulation – the ‘‘highway’’ of cancer cell dis-
semination. Hence, the analysis of CTCs in cancer patients might
give indirect insights into the state tumor cells are in, when they
have reached the blood stream, with the caveat that CTCs can also
originate from existing metastases [84]. A growing body of evi-
dence shows that the presence of CTCs in breast cancer patients
is not only associated with poor prognosis, but it is also predictive
for reduced therapy response. Indeed, CTCs expressing EMT mark-
ers, such as TWIST1 and vimentin, have been identiﬁed in breast
cancer patients [129,130]. One important caveat screening the lit-
erature about CTCs with an EMT phenotype is that the technically
highly demanding analysis of CTCs is often biased toward the
epithelial phenotype, since conventional CTC capture technologies
have been frequently based on epithelial markers, such as EpCAM
and cytokeratins, markers that are lost during a complete EMT
[123,131]. A growing panel of new microﬂuidic CTC-capture
devices now allows the isolation of CTCs of the whole spectrum
from ‘‘fully’’ epithelial to ‘‘fully’’ mesenchymal tumor cells
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proportion of CTCs expressing various levels of mesenchymal
markers is higher in more aggressive breast cancer subtypes and
rises during failure of conventional chemotherapy and targeted
agents [123]. The detection of CTCs expressing mesenchymal
markers and its correlation with parameters of poor clinical out-
come in breast cancer patients suggests therefore the importance
of EMT in the intravasation process. Alternatively, EMT can also
be induced after having reached the blood stream via
EMT-inducing factors, such as TGFb secreted, for example, by pla-
telets that adhere to single-cell CTCs and CTC clusters [7,103,123].
This ‘‘outside of the primary tumor’’ induction of EMT may also be
functionally important by preventing the CTCs from anoikis and
from eradication by chemotherapy and also by supporting extrava-
sation at the distant site.
Although CTC clusters are long known to be important contrib-
utors to metastasis formation [54], it has recently been shown that
in the breast cancer transplantation models CTC-clusters represent
only around 2–5% of CTCs, yet are responsible for approximately
half of the lung metastases. This data reveals a dramatically higher
metastatic potential of CTC clusters compared to single-cell CTCs –
at least in the lung, representing the ﬁrst capillary bed breast can-
cer cells encounter when disseminating systemically. CTC clusters
are mainly derived from oligoclonal aggregates from the primary
tumor rather than being generated by intravascular aggregations
or intravascular proliferation [103]. Interestingly, CTC clusters
can co-express epithelial and mesenchymal markers [123], raising
the question by which mechanism these oligoclonal clumps have
reached the systemic circulation: by collective cell migration or
by passive shedding into the circulation in an epithelial state and
subsequent (partial) EMT induced by platelet-derived TGFb, or by
induction of EMT within the primary tumor and passive shedding
or collective migration of mesenchymal tumor cells into the blood
stream? Certainly, the advances in CTC capturing technologies will
not only provide important new insights into the biology of cancer
cells ‘‘en route’’ from the primary tumor to distant sites [103], but
also open new avenues for new strategies to interfere with metas-
tasis formation [133].
8. Concluding remarks
There is compelling evidence for the existence of carcinoma
cells with a mesenchymal phenotype in human breast cancer as
well as in mouse breast cancer models. Sophisticated lineage-trac
ing experiments as well as novel technologies in single cell analysis
will further shed light into the question whether rare EMT-derived
mesenchymal cells can be found in the tumor stroma. However,
the simple presence of EMT in the primary tumor does not allow
the conclusion that EMT is actually required for metastasis. The
highly complex multistep metastasis cascade and the transient
nature of EMT render it difﬁcult to draw causal conclusions regard-
ing the importance of EMT for metastasis formation in cancer
patients. In addition, mesenchymal migration represents just one
of multiple migration modes cancer cells can employ to leave tis-
sue boundaries, and therapeutically interfering with mesenchymal
migration might activate salvage pathways, such as MAT, or reac-
tivate dormant, mesenchymally disseminated tumor cells by
inducing an MET.
The functional manipulation of key EMT players in breast can-
cer mouse models has provided clear evidence for a causal involve-
ment of EMT-inducing or blocking factors in metastasis.
Unfortunately, EMT marker analysis of the primary tumors derived
from these functional experiments has been rarely reported, and
whether EMT is indeed a prerequisite for metastasis formation
remains to be resolved. In addition, the transient nature of EMTadds another layer of complexity to interpreting the data derived
from these experiments. While temporal resolution can be
achieved by the inducible expression or silencing of genes of inter-
est, spatial resolution as performed by Tsai and co-workers is
urgently needed as well [90].
Despite the impressive progress in the past years, we still need
to learn about the mechanisms underlying cancer metastasis in
mice and men. Animal models that closely recapitulate the patient
situation and the careful design of meaningful clinical studies
accompanied with cutting-edge translational research programs
will be instrumental to transform cancer from a deadly into a
chronic or even curable disease.
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